Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

2,274 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Dose-response to inhaled glycopyrrolate delivered with a novel Co-Suspension™ Delivery Technology metered dose inhaler (MDI) in patients with moderate-to-severe COPD.
Fabbri LM, Kerwin EM, Spangenthal S, Ferguson GT, Rodriguez-Roisin R, Pearle J, Sethi S, Orevillo C, Darken P, St Rose E, Fischer T, Golden M, Dwivedi S, Reisner C. Fabbri LM, et al. Among authors: fischer t. Respir Res. 2016 Sep 2;17(1):109. doi: 10.1186/s12931-016-0426-4. Respir Res. 2016. PMID: 27586537 Free PMC article. Clinical Trial.
Cardiovascular safety of salmeterol in COPD.
Ferguson GT, Funck-Brentano C, Fischer T, Darken P, Reisner C. Ferguson GT, et al. Among authors: fischer t. Chest. 2003 Jun;123(6):1817-24. doi: 10.1378/chest.123.6.1817. Chest. 2003. PMID: 12796155 Clinical Trial.
A multicenter, randomized, double-blind dose-ranging study of glycopyrrolate/formoterol fumarate fixed-dose combination metered dose inhaler compared to the monocomponents and open-label tiotropium dry powder inhaler in patients with moderate-to-severe COPD.
Tashkin DP, Martinez FJ, Rodriguez-Roisin R, Fogarty C, Gotfried M, Denenberg M, Gottschlich G, Donohue JF, Orevillo C, Darken P, St Rose E, Strom S, Fischer T, Golden M, Reisner C. Tashkin DP, et al. Among authors: fischer t. Respir Med. 2016 Nov;120:16-24. doi: 10.1016/j.rmed.2016.09.012. Epub 2016 Sep 17. Respir Med. 2016. PMID: 27817811 Free article. Clinical Trial.
Efficacy and Safety of Glycopyrrolate/Formoterol Metered Dose Inhaler Formulated Using Co-Suspension Delivery Technology in Patients With COPD.
Martinez FJ, Rabe KF, Ferguson GT, Fabbri LM, Rennard S, Feldman GJ, Sethi S, Spangenthal S, Gottschlich GM, Rodriguez-Roisin R, Arora S, Siler TM, Siddiqui S, Darken P, Fischer T, Maes A, Golden M, Orevillo C, Reisner C. Martinez FJ, et al. Among authors: fischer t. Chest. 2017 Feb;151(2):340-357. doi: 10.1016/j.chest.2016.11.028. Epub 2016 Dec 1. Chest. 2017. PMID: 27916620 Free article. Clinical Trial.
A randomized, seven-day study to assess the efficacy and safety of a glycopyrrolate/formoterol fumarate fixed-dose combination metered dose inhaler using novel Co-Suspension™ Delivery Technology in patients with moderate-to-very severe chronic obstructive pulmonary disease.
Reisner C, Fabbri LM, Kerwin EM, Fogarty C, Spangenthal S, Rabe KF, Ferguson GT, Martinez FJ, Donohue JF, Darken P, St Rose E, Orevillo C, Strom S, Fischer T, Golden M, Dwivedi S. Reisner C, et al. Among authors: fischer t. Respir Res. 2017 Jan 6;18(1):8. doi: 10.1186/s12931-016-0491-8. Respir Res. 2017. PMID: 28061907 Free PMC article. Clinical Trial.
Corrigendum to "A multicenter, randomized, double-blind dose-ranging study of glycopyrrolate/formoterol fumarate fixed-dose combination metered dose inhaler compared to the monocomponents and open-label tiotropium dry powder inhaler in patients with moderate-to-severe COPD" [Respir. Med. 120 November 2016 16-24].
Tashkin DP, Martinez FJ, Rodriguez-Roisin R, Fogarty C, Gotfried M, Denenberg M, Gottschlich G, Donohue JF, Orevillo C, Darken P, St Rose E, Strom S, Fischer T, Golden M, Reisner C. Tashkin DP, et al. Among authors: fischer t. Respir Med. 2017 Aug;129:164. doi: 10.1016/j.rmed.2017.06.011. Epub 2017 Jun 30. Respir Med. 2017. PMID: 28732826 Free article. No abstract available.
Erratum to: A randomized, seven-day study to assess the efficacy and safety of a glycopyrrolate/formoterol fumarate fixed-dose combination metered dose inhaler using novel Co-Suspension™ Delivery Technology in patients with moderate-to-very severe chronic obstructive pulmonary disease.
Reisner C, Fabbri LM, Kerwin EM, Fogarty C, Spangenthal S, Rabe KF, Ferguson GT, Martinez FJ, Donohue JF, Darken P, St Rose E, Orevillo C, Strom S, Fischer T, Golden M, Dwivedi S. Reisner C, et al. Among authors: fischer t. Respir Res. 2017 Aug 21;18(1):158. doi: 10.1186/s12931-017-0638-2. Respir Res. 2017. PMID: 28826397 Free PMC article. No abstract available.
Efficacy of Formoterol Fumarate Delivered by Metered Dose Inhaler Using Co-Suspension™ Delivery Technology Versus Foradil® Aerolizer® in Moderate-To-Severe COPD: A Randomized, Dose-Ranging Study.
Sethi S, Fogarty C, Hanania NA, Martinez FJ, Rennard S, Fries M, Orevillo C, Darken P, St Rose E, Strom S, Fischer T, Golden M, Dwivedi S, Reisner C. Sethi S, et al. Among authors: fischer t. Chronic Obstr Pulm Dis. 2016 Nov 17;4(1):21-33. doi: 10.15326/jcopdf.4.1.2016.0158. Chronic Obstr Pulm Dis. 2016. PMID: 28848908 Free PMC article.
Randomized study of the safety, pharmacokinetics, and bronchodilatory efficacy of a proprietary glycopyrronium metered-dose inhaler in study patients with chronic obstructive pulmonary disease.
Rennard S, Fogarty C, Reisner C, Fernandez C, Fischer T, Golden M, Rose ES, Darken P, Tardie G, Orevillo C. Rennard S, et al. Among authors: fischer t. BMC Pulm Med. 2014 Jul 16;14:118. doi: 10.1186/1471-2466-14-118. BMC Pulm Med. 2014. PMID: 25027304 Free PMC article. Clinical Trial.
2,274 results